QuidelOrtho Stock Gains Momentum Following FDA Clearance of New Multiplex test
San Diego, CA – september 27, 2025 – Shares of QuidelOrtho Corporation (Nasdaq: QDEL) are reacting positively today following the Food and Drug administration (FDA) clearance of its new rapid molecular test for simultaneous detection of influenza A/B and COVID-19. The test, designed for point-of-care use, promises faster and more accurate diagnoses during the upcoming respiratory virus season.
QuidelOrtho, a leading provider of diagnostic healthcare solutions, has been focused on innovating rapid testing technologies. This latest advancement builds upon the companyS existing portfolio and addresses the ongoing need for efficient and reliable detection of prevalent respiratory illnesses. The new multiplex test utilizes the company’s molecular platform, delivering results in approximately 30 minutes.
Investors are now evaluating whether the market has fully priced in the potential impact of this new product launch. Simply Wall St’s detailed analysis offers a complete view of QuidelOrtho’s valuation,featuring fair value estimates,potential risks,dividends,insider trades,and its overall financial condition.
Currently, investors can explore undervalued stocks based on cash flows, including opportunities with strong financial upside and growth potential, through Simply Wall St’s screener: https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global.
Access Free Analysis: https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/valuation
Have feedback on this article? Concerned about the content? get in touch with us directly. Alternatively, email editorial-team@simplywallst.com%20from%2027th%20September%202025).
This article by Simply Wall St is general in nature.We provide commentary based on past data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. it does not constitute a suggestion to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
